Navigation Links
ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Date:1/25/2008

TUCSON, Ariz., Jan. 25 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Food and Drug Administration (FDA) has approved the company's most current lot release request for urokinase drug product. This is the first lot to be released with extended expiration dating. Urokinase, ImaRx's first commercially available FDA-approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism.

"The FDA approval of urokinase lot release brings several advantages to ImaRx," said Bradford A. Zakes, President and CEO of ImaRx. "The extended expiration dating allows us to unlock the value from our unlabeled urokinase inventory. We will also benefit from cost-savings associated with prolonged shelf-life for future urokinase supplies."

ImaRx is continuing its stability program to evaluate the potential for further expiration extensions beyond September 2009 for unlabeled vials of urokinase inventory.

In January 2008, ImaRx and Microbix Biosystems Inc. signed a letter of intent to manufacture urokinase and explore development of additional indications. Microbix is believed to be the only supplier capable of producing urokinase on a commercial scale at its production facility in Toronto. As part of the agreement, ImaRx will retain existing urokinase inventory and intends to transfer the manufacturing process and NDA to Microbix. With Microbix as its long-term supplier, ImaRx will continue to market urokinase for acute massive pulmonary embolism, while Microbix will have development rights for certain new indications.

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing thera
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
2. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
3. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
4. Cell Therapeutics, Inc. (CTI) Prices $1.27 million (euros 856.000) Offering of Common Stock through Societe Generale
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. Cell Therapeutics, Inc. Announces Authorization to Publish Italian Listing Prospectus
7. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
8. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
9. Cell Therapeutics, Inc. (CTI) Hosts Conference Call to Discuss Update on Zevalin(R) Acquisition, CMS Reimbursement, and PIX301 Timeline
10. Sirnaomics Received Multiple Government Fundings For Its Multi-Targeted siRNA Therapeutics Programs
11. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... November 2012, the European Union (EU) mandated use of the ... PSUR – responding to the increasing need to understand and ... in many regions, the main objectives of the PBRER are ... analysis of new or emerging information on the risks of ... the potential benefits of a drug; and , ...
(Date:8/18/2014)... 19, 2014 2014 Deep Research ... a professional and in-depth research report on the ... information, including its definition, classification, application, and ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis. ...
(Date:8/18/2014)... , Aug. 18, 2014   Sterne, Kessler, Goldstein ... in Washington, DC , announced today ... Partes Review (IPR) with the U.S. Patent and ... subsidiary of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR ... licensed by Myriad Genetics, Inc. These patents have been ...
(Date:8/18/2014)... 18, 2014 According to ... By Application (Municipal Wastewater Treatment and Industrial Wastewater ... Multi Tubular), By Configuration (Internal/Submerged and External/Sidestream), and ... MarketsandMarkets, The market for membrane bioreactor systems is ... at a CAGR of 15.28% between 2014 and ...
Breaking Biology Technology:Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3
... Jan. 3 Thoratec,Corporation (Nasdaq: THOR ), ... said today that it will be participating in ... Gary Burbach, president and chief executive officer, ... 8:30 a.m., Pacific Standard Time (11:30,a.m., Eastern Standard ...
... and CLAREMONT, Calif., Jan. 3 /Xinhua-PRNewswire-FirstCall/ --,Kiwa ... successful,exhibition of its Fertilizer Products in Dingxing, ... representatives with large volume distribution,businesses in 7 ... the exhibition,and agreements were reached with local ...
... 3 /PRNewswire/-- Intercept Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical ... fibrotic and metabolic diseases, today announced the,appointment ... created position of,Chief Scientific Officer. Dr. Adorini ... research and development, recently serving as Chief ...
Cached Biology Technology:Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 2Kiwa Bio-Tech Products Group Holds a Fertilizer Products Exhibition in Hebei 3Intercept Pharmaceuticals Names Dr. Luciano Adorini Chief Scientific Officer 2
(Date:8/20/2014)... and POINT ROBERTS, Washington , August 20, ... Key Role in Addressing Security Concerns in the Payment Industry? ... news source covering leading sectors including biometrics, issues commentary from ... Jason Peaslee , Managing Partner at Thrive Analytics, ... Gino Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( ...
(Date:8/19/2014)... to decrease China,s increasing caesarean section rate, suggests a ... An International Journal of Obstetrics and Gynaecology (BJOG) . ... rates in the world. Of 16 million babies born ... exact rate is not known, the current Chinese language ... rates ranging from 36% to 58%. However, before the ...
(Date:8/19/2014)... in supermarkets to encourage healthier spending habits? A new ... very question by tracking the purchasing records in a ... rate the nutritional value of foods for sale. , ... Just, PhD, and Brian Wansink PhD, author of Slim ... 150 Hannaford Supermarkets in the Northeastern United States between ...
Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
... a virulent family of bacteria called Yersinia, a group ... These bacteria insert into their host cells proteins and ... things -- disrupting the cells' normal structure. One of ... Now, a study published by Rockefeller University researchers in ...
... tend to have a much lower quality of life when they ... in the latest issue of the UK-based Journal of Advanced Nursing. ... 1500g or less and compared them with a control group of ... when it came to physical, emotional, cognitive and social functions. , ...
... a little mean sometimes ?especially when there's a choice bit ... flies have shorter tempers than others. , Researchers in ... suite of genes that affect aggression in the fruit fly ... abnormal aggression in humans and other animals. , The ...
Cached Biology News:A wolf in sheep's clothing: Plague bacteria reveal one of their virulence tricks 2Very low birth weight linked to reduced quality of life in pre-school children 2Fruit fly aggression studies have relevance to humans, animals 2Fruit fly aggression studies have relevance to humans, animals 3
Request Info...
Agarose, low melting/gelling temperature, high MW separation (>1000 bp), 25 g. Suitable for enzymatic modifications. Nuclease-free.Gel point: 24-30 C, EEO (-mr): 300 gm/cm2. Category: Nucleotides &...
Request Info...
Request Info...
Biology Products: